Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
12 November 2021 - 2:09PM
Cellectis Presents First Preclinical Data on UCARTMESO, an
Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to
Treat Solid Tumors at the Annual Meeting of the Society for
Immunotherapy of Cancer
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the
“Company”), a clinical-stage gene-editing company employing its
core technology to develop products based on gene-editing with a
portfolio of allogeneic chimeric antigen receptor (CAR-)T cells in
the field of immuno-oncology and gene-edited hematopoietic stem
cells in other indications, announced the first preclinical data on
UCARTMESO, its allogeneic CAR-T cell product candidate targeting
mesothelin, being developed for patients
with mesothelin-expressing solid tumors.
The data were presented today in a poster
session at the Society for Immunotherapy of Cancer (SITC) 36th
Annual Meeting titled “Mesothelin (MSLN) targeting allogeneic CAR-T
cells engineered to overcome tumor immunosuppressive
microenvironment”. Poster # 143.
The poster presentation highlighted the
following preclinical data:
- Mesothelin is an interesting target
for CAR-T cell therapy for solid tumors because it is highly and
consistently expressed in mesothelioma and pancreatic cancers. It
is also over-expressed in subsets of other solid tumors (ovarian
cancer, non-small cell lung cancer, gastric cancer, triple-negative
breast cancer) while modestly expressed in healthy cells,
indicating that targeting mesothelin may result in a safe and
effective therapy.
- UCARTMESO product candidate is
composed of allogeneic non-alloreactive T cells edited with
TALEN®-encoding mRNAs to disrupt TRAC, CD52 and TGFBR2 genes, and
transduced ex vivo with a recombinant lentiviral vector (rLV)
to express a second-generation CAR targeting MSLN. It is the first
TALEN®-induced triple knock out (KO) product candidate in the
allogeneic CAR-T space.
- The preclinical data demonstrated
potent activity of UCARTMESO in vitro and in vivo against MSLN
expressing cell lines, and in vivo activity in pancreatic and
pleural mesothelioma mouse models.
- Due to TGFBR2 KO, UCARTMESO was
shown to restore IL2RA upregulation upon in vitro activation, even
in media rich in TGFB1, which contributes to the immune suppressive
microenvironment in tumors.
Laurent Poirot, PhD, Senior Vice President
Immunology, noted: “Overall, the data demonstrated that the TGFBR2
gene knock out provides valuable additional properties to
UCARTMESO, which may result in a very effective therapy despite an
immune suppressive tumor microenvironment, and supports its
clinical development for the treatment of solid tumors.”
A copy of the presentation will be available on
Cellectis’ website here, shortly after the event.
About Cellectis Cellectis
is a gene editing company, developing first of its kind therapeutic
products. Cellectis utilizes an allogeneic approach for CAR-T
immunotherapies in oncology, pioneering the concept of
off-the-shelf and ready-to-use gene-edited CAR T-cells to treat
cancer patients, and a platform to make therapeutic gene editing in
hemopoietic stem cells for various diseases. As a clinical-stage
biopharmaceutical company with over 21 years of expertise in gene
editing, Cellectis is developing life-changing product candidates
utilizing TALEN®, its gene editing technology, and PulseAgile,
its pioneering electroporation system to harness the power of the
immune system in order to treat diseases with unmet
medical needs. As part of its commitment to a cure,
Cellectis remains dedicated to its goal of providing lifesaving
UCART product candidates for multiple cancers including acute
myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL)
and multiple myeloma (MM). .HEAL is a new platform
focusing on hemopoietic stem cells to treat blood disorders,
immunodeficiencies and lysosomial storage
diseases. Cellectis headquarters are in Paris, France,
with locations in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and
on Euronext Growth (ticker: ALCLS).
For more information,
visit www.cellectis.com Follow
Cellectis on social media: @cellectis, LinkedIn and
YouTube.
For further information, please
contact:
Media contacts: Margaret Gandolfo, Senior
Manager, Communications, +1 (646) 628 0300 Pascalyne
Wilson, Director, Communications, +33776991433,
media@cellectis.com
Investor Relation
contact: Eric Dutang, Chief Financial
Officer, +1 (646) 630
1748, investor@cellectis.com
Forward-looking Statements
This presentation contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as “at
this time,” “anticipate,” “believe,” “expect,” “on track,” “plan,”
“scheduled,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, include statements
about our research and development projects and priorities, our
pre-clinical project development efforts and the timing of our
presentation of data. These forward-looking statements are made in
light of information currently available to us and are subject to
numerous risks and uncertainties, including with respect to the
numerous risks associated with biopharmaceutical product candidate
development as well as the duration and severity of the COVID-19
pandemic and governmental and regulatory measures implemented in
response to the evolving situation. With respect to our cash
runway, our operating plans, including product development plans,
may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2020 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- NEW_20211111_CLLS_SITC PR _ ENGLISH_
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Historical Stock Chart
Von Apr 2023 bis Apr 2024